BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 26053727)

  • 41. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
    Naswa N; Sharma P; Suman Kc S; Lata S; Kumar R; Malhotra A; Bal C
    Nucl Med Commun; 2012 Jul; 33(7):766-74. PubMed ID: 22531829
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Utility of ¹⁸F-FDG PET/CT in identifying penile squamous cell carcinoma metastatic lymph nodes.
    Rosevear HM; Williams H; Collins M; Lightfoot AJ; Coleman T; Brown JA
    Urol Oncol; 2012 Sep; 30(5):723-6. PubMed ID: 21396850
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Diagnostic performance of
    Ishiguchi H; Ito S; Kato K; Sakurai Y; Kawai H; Fujita N; Abe S; Narita A; Nishio N; Muramatsu H; Takahashi Y; Naganawa S
    Ann Nucl Med; 2018 Jun; 32(5):348-362. PubMed ID: 29667143
    [TBL] [Abstract][Full Text] [Related]  

  • 44. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
    Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
    Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
    [TBL] [Abstract][Full Text] [Related]  

  • 45. 18F-fluorodeoxyglucose positron emission tomography-computed tomography for suspected recurrent papillary thyroid cancer: early experience at Sunnybrook Health Sciences Centre.
    Dahele M; Ung YC; Ehrlich L; Silverberg J; Balogh J; Wong CS
    J Otolaryngol Head Neck Surg; 2008 Oct; 37(5):712-7. PubMed ID: 19128681
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma.
    Triviño Ibáñez EM; Muros MA; Torres Vela E; Llamas Elvira JM
    Endocrine; 2016 Mar; 51(3):490-8. PubMed ID: 26224589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. F-18-fluorodeoxyglucose positron emission tomography as a presurgical evaluation modality for I-131 scan-negative thyroid carcinoma patients with local recurrence in cervical lymph nodes.
    Yeo JS; Chung JK; So Y; Kim S; Lee E; Lee DS; Youn YK; Hong SJ; Ahn IM; Lee MC; Cho BY
    Head Neck; 2001 Feb; 23(2):94-103. PubMed ID: 11303639
    [TBL] [Abstract][Full Text] [Related]  

  • 48. ¹⁸F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study.
    Piccardo A; Puntoni M; Bertagna F; Treglia G; Foppiani L; Arecco F; Giubbini R; Naseri M; Cistaro A; Cabria M; Bardesono F; Ceriani L; Orlandi F; Giovanella L
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1482-91. PubMed ID: 24781870
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of 18F-AIF-NOTA-PRGD2 and 18F-FDG uptake in lymph node metastasis of differentiated thyroid cancer.
    Cheng W; Wu Z; Liang S; Fu H; Wu S; Tang Y; Ye Z; Wang H
    PLoS One; 2014; 9(6):e100521. PubMed ID: 24956393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Patterns of nodal metastases on 18F-FDG PET/CT in patients with esophageal squamous cell carcinoma are useful to guide treatment planning of radiotherapy.
    Liu CJ; Cheng JC; Lee JM; Cheng MF; Tzen KY; Yen RF
    Clin Nucl Med; 2015 May; 40(5):384-9. PubMed ID: 25674870
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of whole-body 18F-FDG PET, 99mTc-MIBI SPET, and post-therapeutic 131I-Na scintigraphy in the detection of metastatic thyroid cancer.
    Iwata M; Kasagi K; Misaki T; Matsumoto K; Iida Y; Ishimori T; Nakamoto Y; Higashi T; Saga T; Konishi J
    Eur J Nucl Med Mol Imaging; 2004 Apr; 31(4):491-8. PubMed ID: 14666387
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinoma.
    De Luca S; Fonti R; Camera L; Salvatore B; Faggiano A; Ciarmiello A; Segreto S; Colao A; Salvatore M; Del Vecchio S
    Ann Nucl Med; 2016 Apr; 30(3):234-41. PubMed ID: 26753628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FDG-PET/CT for the preoperative lymph node staging of invasive bladder cancer.
    Swinnen G; Maes A; Pottel H; Vanneste A; Billiet I; Lesage K; Werbrouck P
    Eur Urol; 2010 Apr; 57(4):641-7. PubMed ID: 19477579
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Therapeutic impact of 18FDG-PET/CT in the management of iodine-negative recurrence of differentiated thyroid carcinoma.
    Mirallié E; Guillan T; Bridji B; Resche I; Rousseau C; Ansquer C; Bodet-Milin C; Curtet C; Carnaille B; Murat A; Charbonnel B; Kraeber-Bodéré F
    Surgery; 2007 Dec; 142(6):952-8; discussion 952-8. PubMed ID: 18063081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of diagnostic and prognostic capabilities of ¹⁸F-FDG-PET/CT, ¹³¹I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer.
    Nagamachi S; Wakamatsu H; Kiyohara S; Nishii R; Mizutani Y; Fujita S; Futami S; Arita H; Kuroki M; Nakada H; Uchino N; Tamura S; Kawai K
    Jpn J Radiol; 2011 Jul; 29(6):413-22. PubMed ID: 21786097
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Diagnostic accuracy of dual-time-point 18F-FDG PET/CT for the detection of axillary lymph node metastases in breast cancer patients.
    Hahn S; Hecktor J; Grabellus F; Hartung V; Pöppel T; Kimmig R; Forsting M; Antoch G; Heusner TA
    Acta Radiol; 2012 Jun; 53(5):518-23. PubMed ID: 22547387
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A rare case of metastatic clear cell carcinoma of the Müllerian system originating from the peritoneum assessed by 18F-FDG PET/CT.
    Treglia G; Barizzi J; Paone G; Ceriani L; Bongiovanni M; Giovanella L
    Clin Nucl Med; 2015 Jan; 40(1):e58-60. PubMed ID: 24561679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The use of multiple time point dynamic positron emission tomography/computed tomography in patients with oral/head and neck cancer does not predictably identify metastatic cervical lymph nodes.
    Carlson ER; Schaefferkoetter J; Townsend D; McCoy JM; Campbell PD; Long M
    J Oral Maxillofac Surg; 2013 Jan; 71(1):162-77. PubMed ID: 22742956
    [TBL] [Abstract][Full Text] [Related]  

  • 60. 18F-FDG-PET/CT is of limited value in primary staging of early stage cervical cancer.
    Driscoll DO; Halpenny D; Johnston C; Sheehy N; Keogan M
    Abdom Imaging; 2015 Jan; 40(1):127-33. PubMed ID: 25015401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.